[go: up one dir, main page]

JP7489385B2 - シクロスポリン類似体の医薬製剤 - Google Patents

シクロスポリン類似体の医薬製剤 Download PDF

Info

Publication number
JP7489385B2
JP7489385B2 JP2021529703A JP2021529703A JP7489385B2 JP 7489385 B2 JP7489385 B2 JP 7489385B2 JP 2021529703 A JP2021529703 A JP 2021529703A JP 2021529703 A JP2021529703 A JP 2021529703A JP 7489385 B2 JP7489385 B2 JP 7489385B2
Authority
JP
Japan
Prior art keywords
smedds
crv431
subject
hours
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021529703A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020112562A5 (da
JP2022513635A (ja
Inventor
ダニエル ジョセフ トレパニエ
ダレン レイモンド ウレ
ロバート トーマス フォスター
Original Assignee
ヘピオン ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘピオン ファーマシューティカルズ インコーポレイテッド filed Critical ヘピオン ファーマシューティカルズ インコーポレイテッド
Publication of JP2022513635A publication Critical patent/JP2022513635A/ja
Publication of JPWO2020112562A5 publication Critical patent/JPWO2020112562A5/ja
Application granted granted Critical
Publication of JP7489385B2 publication Critical patent/JP7489385B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021529703A 2018-11-26 2019-11-22 シクロスポリン類似体の医薬製剤 Active JP7489385B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862771453P 2018-11-26 2018-11-26
US62/771,453 2018-11-26
PCT/US2019/062849 WO2020112562A1 (en) 2018-11-26 2019-11-22 Pharmaceutical formulations of cyclosporine analogs

Publications (3)

Publication Number Publication Date
JP2022513635A JP2022513635A (ja) 2022-02-09
JPWO2020112562A5 JPWO2020112562A5 (da) 2022-12-02
JP7489385B2 true JP7489385B2 (ja) 2024-05-23

Family

ID=68916602

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529703A Active JP7489385B2 (ja) 2018-11-26 2019-11-22 シクロスポリン類似体の医薬製剤

Country Status (28)

Country Link
US (3) US20200163876A1 (da)
EP (1) EP3886813B1 (da)
JP (1) JP7489385B2 (da)
KR (1) KR20210099038A (da)
CN (1) CN113194927B (da)
AR (1) AR117150A1 (da)
AU (1) AU2019386859A1 (da)
BR (1) BR112021009967A2 (da)
CA (1) CA3120015A1 (da)
CY (1) CY1126071T1 (da)
DK (1) DK3886813T3 (da)
ES (1) ES2942473T3 (da)
FI (1) FI3886813T3 (da)
HR (1) HRP20230548T1 (da)
HU (1) HUE061877T2 (da)
IL (1) IL283286A (da)
LT (1) LT3886813T (da)
MX (1) MX2021006010A (da)
PH (1) PH12021551086A1 (da)
PL (1) PL3886813T3 (da)
PT (1) PT3886813T (da)
RS (1) RS64239B1 (da)
SG (1) SG11202105336TA (da)
SI (1) SI3886813T1 (da)
SM (1) SMT202300139T1 (da)
TW (1) TWI844585B (da)
WO (1) WO2020112562A1 (da)
ZA (1) ZA202103090B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021224676A1 (en) 2020-02-19 2022-09-08 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues for treating fibrosis
US20210269479A1 (en) 2020-02-25 2021-09-02 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues for treating cancer
EP4251189A1 (en) 2020-11-29 2023-10-04 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues as antithrombotic agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525363A (ja) 1997-12-10 2001-12-11 シクロスポリン セラポイティクス リミテッド オメガ−３脂肪酸油を含む医薬組成物
JP2002505271A (ja) 1998-03-06 2002-02-19 ノバルティス アクチエンゲゼルシャフト サイクロスポリン類またはマクロライド含有エマルジョン前濃縮物
JP2003512312A (ja) 1999-10-20 2003-04-02 ヴェジファクト・アクチェンゲゼルシャフト マイクロエマルジョン予備濃縮物、マイクロエマルジョンおよび組成物の使用
JP2005500314A (ja) 2001-06-21 2005-01-06 ファイザー・プロダクツ・インク コレステロールエステル転送蛋白インヒビターの自己乳化性製剤
US20180296588A1 (en) 2017-04-14 2018-10-18 Contravir Pharmaceuticals, Inc. Combination therapy for treating viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US6262022B1 (en) * 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
DE60233150D1 (de) * 2001-10-19 2009-09-10 Isotechnika Inc Neue cyclosporin-analoge mikroemulsionsvorkonzentrate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001525363A (ja) 1997-12-10 2001-12-11 シクロスポリン セラポイティクス リミテッド オメガ−３脂肪酸油を含む医薬組成物
JP2002505271A (ja) 1998-03-06 2002-02-19 ノバルティス アクチエンゲゼルシャフト サイクロスポリン類またはマクロライド含有エマルジョン前濃縮物
JP2003512312A (ja) 1999-10-20 2003-04-02 ヴェジファクト・アクチェンゲゼルシャフト マイクロエマルジョン予備濃縮物、マイクロエマルジョンおよび組成物の使用
JP2005500314A (ja) 2001-06-21 2005-01-06 ファイザー・プロダクツ・インク コレステロールエステル転送蛋白インヒビターの自己乳化性製剤
US20180296588A1 (en) 2017-04-14 2018-10-18 Contravir Pharmaceuticals, Inc. Combination therapy for treating viral infections

Also Published As

Publication number Publication date
ES2942473T3 (es) 2023-06-01
IL283286A (en) 2021-07-29
DK3886813T3 (da) 2023-05-01
KR20210099038A (ko) 2021-08-11
MX2021006010A (es) 2021-09-21
US20230390198A1 (en) 2023-12-07
TWI844585B (zh) 2024-06-11
AR117150A1 (es) 2021-07-14
BR112021009967A2 (pt) 2021-08-17
LT3886813T (lt) 2023-04-11
SMT202300139T1 (it) 2023-07-20
ZA202103090B (en) 2023-09-27
PT3886813T (pt) 2023-04-26
PL3886813T3 (pl) 2023-06-19
EP3886813B1 (en) 2023-03-22
JP2022513635A (ja) 2022-02-09
CN113194927A (zh) 2021-07-30
TW202038911A (zh) 2020-11-01
HRP20230548T1 (hr) 2023-08-04
WO2020112562A1 (en) 2020-06-04
PH12021551086A1 (en) 2022-01-03
EP3886813A1 (en) 2021-10-06
CN113194927B (zh) 2023-10-27
US20230390199A1 (en) 2023-12-07
US20200163876A1 (en) 2020-05-28
SI3886813T1 (sl) 2023-05-31
AU2019386859A1 (en) 2021-05-27
CY1126071T1 (el) 2023-11-15
RS64239B1 (sr) 2023-06-30
CA3120015A1 (en) 2020-06-04
FI3886813T3 (fi) 2023-05-04
SG11202105336TA (en) 2021-06-29
HUE061877T2 (hu) 2023-08-28

Similar Documents

Publication Publication Date Title
JP7489385B2 (ja) シクロスポリン類似体の医薬製剤
CN115052584B (zh) 治疗性化合物及其制剂和用途
TW202139984A (zh) 治療性化合物及其調配物與用途
JP2018027949A (ja) 医薬組成物
Trepanier et al. Development, characterization, and pharmacokinetic evaluation of a crv431 loaded self-microemulsifying drug delivery system
JP2009509942A (ja) フルベストラント製剤
RU2810897C2 (ru) Фармацевтические составы аналогов циклоспорина
WO2014075554A1 (zh) 含有西罗莫司酯化物的药物组合物及其制备方法
US20250057807A1 (en) Treating a disease using a pharmaceutically active ingredient present in a pseudo-ternary phase system
HK40057624B (en) Pharmaceutical formulations of cyclosporine analogs
HK40057624A (en) Pharmaceutical formulations of cyclosporine analogs
JPWO2020112562A5 (da)
CN111712231A (zh) 用于40-o-环状烃酯和相关结构的肠胃外制剂材料和方法
EA046628B1 (ru) Терапевтические соединения, их составы и применения
RU2021113369A (ru) Фармацевтические композиции аналогов циклоспорина
KR20240032997A (ko) 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온을 포함하는 약제학적 조성물
HK40044248A (en) Treatment method with iap inhibitor
CN112891510A (zh) 采用iap抑制剂的治疗方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240321

R155 Notification before disposition of declining of application

Free format text: JAPANESE INTERMEDIATE CODE: R155

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240513

R150 Certificate of patent or registration of utility model

Ref document number: 7489385

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150